AMSTERDAM, the Netherlands (March 7, 2017)—Royal Philips, today announced the expansion of its Dream Family of products with the new DreamStation Advanced Therapies platform designed to deliver optimal ventilation with minimal mechanical intervention. Through these new offerings, DreamStation now supports the most complex patient cases—those suffering with sleep-disordered breathing and respiratory insufficiencies.
Worldwide, more than 100 million people have obstructive sleep apnea (OSA), with recent research revealing that a significant percentage of these patients suffer from more complex sleep-disordered breathing. Chronic respiratory illness impacts a significant population worldwide, with an estimated 65 million suffering from Chronic Obstructive Pulmonary Disorder (COPD), and even more suffering from specific respiratory insufficiencies due to other chronic or neuromuscular diseases, all requiring unique therapy. To address the varying needs of these complex disorders, Philips designed the DreamStation Advanced Therapies BiPAP autoSV and AVAPS devices. Built on sophisticated, clinically-proven algorithms, BiPAP autoSV aims to deliver optimal ventilation with minimal intervention so patients experience comfortable, restful sleep, while BiPAP AVAPS is designed to deliver effective and comfortable ventilation therapy so patients can experience an improved quality of life.
“Treating patients with complex breathing disorders is not always straightforward, and every patient has unique therapy needs that can change night to night,” said Mark D’Angelo, sleep therapy business leader, Philips Sleep & Respiratory Care. “In addition to medical support, they require guidance and encouragement. With these updates to our Dream Family, we can provide individualized support for a wider range patients and empower clinicians to deliver the most efficient and best care possible.”
As with all Dream Family solutions, the DreamStation Advanced Therapies are fully-integrated through Philips Encore Anywhere patient management tool. This connectivity provides automated support for the patient’s specific and changing needs as well as remote monitoring capabilities support for physicians, durable medical equipment (DME) providers and caretakers to intervene when needed to minimalize adverse events.
Currently available in in select markets including France, Australia and the United States, the devices are expected to become available globally by the end of 2017. The Philips Dream Family of products launched in 2015 as a full suite of sleep solutions that connect and support the patient, clinician and homecare provider to enhance patient care and quality of life. With the launch of DreamStation Advanced Therapies AVAPS device, Philips expands the Dream Family to feature respiratory solutions.
Visit philips.com for more information.
